After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
ALLO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Allogene Therapeutics Inc is $257.38M. A total of 3.75 million shares were traded on the day, compared to an average of 4.06M shares.
In the most recent transaction, MESSEMER DEBORAH M. sold 36,885 shares of ALLO for 1.42 per share on Jun 10 ’25. After the transaction, the Director now owns 107,431 company shares. In a previous transaction on Jun 10 ’25, MESSEMER DEBORAH M. bought 36,885 shares at 1.42 per share.
Among the insiders who sold shares, Yoshiyama Annie disposed of 9,601 shares on Apr 21 ’25 at a per-share price of $1.41. This resulted in the SVP, Finance holding 130,663 shares of ALLO after the transaction. In another insider transaction, Yoshiyama Annie bought 9,601 shares at $1.41 per share on Apr 21 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ALLO has a high of $3.78 and a low of $0.86.
As of this writing, ALLO has an earnings estimate of -$0.23 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.21 per share and a lower estimate of -$0.24. The company reported an EPS of -$0.27 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $47.91M in liabilities at the time. Its Book Value Per Share was $1.57, while its Total Shareholder’s Equity was $925.20M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock.
